Epigral Stock Falls to 52-Week Low of Rs.1400 Amidst Mixed Financial Signals

Stock Price Movement and Market Context

On 25 Nov 2025, Epigral's share price touched Rs.1400, the lowest level recorded in the past 52 weeks. Despite this, the stock outperformed its sector by 0.9% on the day, indicating some relative resilience within its industry group. However, the stock remains below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a sustained downward trend in price momentum.

In contrast, the broader market environment shows a more positive tone. The Sensex opened higher at 85,008.93 points, gaining 108.22 points (0.13%) before trading slightly lower at 84,964.83 points (0.08%). The index is currently 0.98% away from its 52-week high of 85,801.70 points and is trading above its 50-day moving average, which itself is positioned above the 200-day moving average, reflecting a bullish trend in the broader market. Mid-cap stocks are leading gains with the BSE Mid Cap index rising by 0.11% on the day.

Long-Term and Recent Performance Metrics

Over the last year, Epigral's stock has recorded a return of -28.18%, contrasting with the Sensex's positive 6.07% return over the same period. The stock's 52-week high was Rs.2195.85, highlighting the extent of the decline to the current low. This underperformance extends beyond the last year, with the stock also lagging behind the BSE500 index over the past three years, one year, and three months.

Financially, the company has experienced a contraction in operating profit at an annual rate of -5.49% over the past five years. The most recent quarterly results for September 2025 show a mixed picture: operating profit to net sales ratio stood at 22.53%, the lowest recorded, while profit after tax (PAT) for the quarter was Rs.51.22 crores, reflecting a decline of 52.6% compared to the previous four-quarter average. Meanwhile, interest expenses for the latest six months were Rs.45.21 crores, representing a growth of 286.41%, indicating increased financing costs.

Financial Strength and Efficiency Indicators

Despite the challenges reflected in profitability and stock price, Epigral demonstrates notable strengths in management efficiency and financial stability. The company reports a return on capital employed (ROCE) of 23.19%, which is considered high and indicative of effective utilisation of capital resources. Additionally, the debt servicing capability appears robust, with a low debt to EBITDA ratio of 1.34 times, suggesting manageable leverage levels relative to earnings before interest, taxes, depreciation, and amortisation.

Valuation metrics also provide some context for the stock's current pricing. The company’s ROCE of 19.3% aligns with a fair valuation, supported by an enterprise value to capital employed ratio of 2.5. Compared to its peers, Epigral is trading at a discount relative to average historical valuations, which may reflect market caution given recent financial results and price trends.

Interestingly, while the stock has declined by 28.18% over the past year, the company’s profits have shown an increase of 37.1% during the same period. This divergence is captured by a price/earnings to growth (PEG) ratio of 0.5, indicating that profit growth has outpaced the stock price movement.

Shareholding and Sector Position

Epigral operates within the Specialty Chemicals industry and sector, where it faces competition and market dynamics that influence its performance. The majority shareholding is held by promoters, which often provides a degree of stability in ownership structure. The company’s market capitalisation grade is noted as 3, reflecting its size and market presence within the sector.

On the trading day when the 52-week low was recorded, the stock’s day change was 0.94%, indicating some positive movement despite the overall low price level. This suggests that while the stock is at a significant low, there remains some trading activity and interest in the shares.

Summary of Key Financial and Market Data

To summarise, Epigral’s stock price at Rs.1400 marks a notable 52-week low, reflecting a period of price weakness amid mixed financial results. The company’s long-term operating profit trend shows a contraction, while recent quarterly results reveal a decline in profit after tax and a rise in interest expenses. Conversely, management efficiency and debt servicing metrics remain strong, with a high ROCE and low debt to EBITDA ratio. The stock trades below all major moving averages and has underperformed the broader market indices over the past year and longer periods.

Market conditions for the broader indices remain positive, with the Sensex near its 52-week high and mid-cap stocks leading gains. Epigral’s relative performance within its sector shows some outperformance on the day of the new low, but the overall trend remains subdued.

Conclusion

Epigral’s current stock price level at its 52-week low of Rs.1400 reflects a complex interplay of financial performance, market sentiment, and sector dynamics. While certain financial indicators point to challenges, other metrics highlight operational strengths and valuation considerations. This multifaceted picture underscores the importance of analysing a broad range of data points when assessing the stock’s position within the Specialty Chemicals sector.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →